BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 10497030)

  • 1. Recruiting Zn2+ to mediate potent, specific inhibition of serine proteases.
    Katz BA; Luong C
    J Mol Biol; 1999 Sep; 292(3):669-84. PubMed ID: 10497030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of potent selective zinc-mediated serine protease inhibitors.
    Katz BA; Clark JM; Finer-Moore JS; Jenkins TE; Johnson CR; Ross MJ; Luong C; Moore WR; Stroud RM
    Nature; 1998 Feb; 391(6667):608-12. PubMed ID: 9468142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxyanion-mediated inhibition of serine proteases.
    Presnell SR; Patil GS; Mura C; Jude KM; Conley JM; Bertrand JA; Kam CM; Powers JC; Williams LD
    Biochemistry; 1998 Dec; 37(48):17068-81. PubMed ID: 9836602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
    Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
    J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
    Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
    J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X-ray crystallographic analyses of complexes between bovine beta-trypsin and Schiff base copper(II) or iron(III) chelates.
    Toyota E; Ng KK; Sekizaki H; Itoh K; Tanizawa K; James MN
    J Mol Biol; 2001 Jan; 305(3):471-9. PubMed ID: 11152605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety.
    Malikayil JA; Burkhart JP; Schreuder HA; Broersma RJ; Tardif C; Kutcher LW; Mehdi S; Schatzman GL; Neises B; Peet NP
    Biochemistry; 1997 Feb; 36(5):1034-40. PubMed ID: 9033393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affinity and specificity of serine endopeptidase-protein inhibitor interactions. Empirical free energy calculations based on X-ray crystallographic structures.
    Krystek S; Stouch T; Novotny J
    J Mol Biol; 1993 Dec; 234(3):661-79. PubMed ID: 8254666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution.
    Katz BA; Liu B; Barnes M; Springman EB
    Protein Sci; 1998 Apr; 7(4):875-85. PubMed ID: 9568894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bis(5-amidino-2-benzimidazolyl)methane and related amidines are potent, reversible inhibitors of mast cell tryptases.
    Caughey GH; Raymond WW; Bacci E; Lombardy RJ; Tidwell RR
    J Pharmacol Exp Ther; 1993 Feb; 264(2):676-82. PubMed ID: 8437115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human alpha-thrombin inhibition by the active site titrant N alpha-(N,N-dimethylcarbamoyl)-alpha-azalysine p-nitrophenyl ester: a comparative kinetic and X-ray crystallographic study.
    Nardini M; Pesce A; Rizzi M; Casale E; Ferraccioli R; Balliano G; Milla P; Ascenzi P; Bolognesi M
    J Mol Biol; 1996 May; 258(5):851-9. PubMed ID: 8637015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition.
    Dullweber F; Stubbs MT; Musil D; Stürzebecher J; Klebe G
    J Mol Biol; 2001 Oct; 313(3):593-614. PubMed ID: 11676542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes.
    Krishnan R; Zhang E; Hakansson K; Arni RK; Tulinsky A; Lim-Wilby MS; Levy OE; Semple JE; Brunck TK
    Biochemistry; 1998 Sep; 37(35):12094-103. PubMed ID: 9724521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compromise and accommodation in ecotin, a dimeric macromolecular inhibitor of serine proteases.
    Gillmor SA; Takeuchi T; Yang SQ; Craik CS; Fletterick RJ
    J Mol Biol; 2000 Jun; 299(4):993-1003. PubMed ID: 10843853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro inhibition of human sarcoma cells' invasive ability by bis(5-amidino-2-benzimidazolyl)methane--a novel esteroprotease inhibitor.
    Cresson DH; Beckman WC; Tidwell RR; Geratz JD; Siegal GP
    Am J Pathol; 1986 Apr; 123(1):46-56. PubMed ID: 3008561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.
    Verner E; Katz BA; Spencer JR; Allen D; Hataye J; Hruzewicz W; Hui HC; Kolesnikov A; Li Y; Luong C; Martelli A; Radika K; Rai R; She M; Shrader W; Sprengeler PA; Trapp S; Wang J; Young WB; Mackman RL
    J Med Chem; 2001 Aug; 44(17):2753-71. PubMed ID: 11495587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of peptide bonds to inhibitor-protease binding: crystal structures of the turkey ovomucoid third domain backbone variants OMTKY3-Pro18I and OMTKY3-psi[COO]-Leu18I in complex with Streptomyces griseus proteinase B (SGPB) and the structure of the free inhibitor, OMTKY-3-psi[CH2NH2+]-Asp19I.
    Bateman KS; Huang K; Anderson S; Lu W; Qasim MA; Laskowski M; James MN
    J Mol Biol; 2001 Jan; 305(4):839-49. PubMed ID: 11162096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-function relationship of serine protease-protein inhibitor interaction.
    Otlewski J; Jaskólski M; Buczek O; Cierpicki T; Czapińska H; Krowarsch D; Smalas AO; Stachowiak D; Szpineta A; Dadlez M
    Acta Biochim Pol; 2001; 48(2):419-28. PubMed ID: 11732612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.